Evaluation of treatment efficacy of the 161Tb- and 177Lu-Labeled GRPR antagonists AMTG and RM2 in a mouse model of prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging · Published 2026-07-10 · DOI 10.1007/s00259-026-08035-6

Free full text

Authors (9)

Thomas Günther, Abraham S. Moses, Elisabeth Günther, Madeleine R. Landry, Stijn Ramaekers, Michiel Van de Voorde, Maarten Ooms, Bernard Ponsard, Corinne Beinat

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Günther, T., Moses, A., Günther, E., et al. (2026). Evaluation of treatment efficacy of the 161Tb- and 177Lu-Labeled GRPR antagonists AMTG and RM2 in a mouse model of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08035-6

Related articles

• Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort · European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Same journal
• Whole-body TSPO-PET reveals stage-dependent disruption of systemic immune organ interactions in glioblastoma · European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Same journal
• From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment · European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Same journal
• [18F]FDG PET during immunotherapy: mind the gap between evidence, imaging guidelines, and oncology practice · European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Same journal
• CSF proteomic pathway alterations and caudate dopamine transporter deficits predict cognitive vulnerability in early Parkinson’s disease · European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Same journal
• Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy · European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Same journal
• In vivo multimodal PET/MRI imaging and plasma biomarkers implicate glymphatic dysfunction linking neuroinflammation to tau pathology in the early Alzheimer’s disease continuum · European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Same journal
• Prospective comparison of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer · European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Same journal
• 68Ga-PSMA PET/CT in biochemically recurrent prostate cancer: association with genomic data · European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Same journal
• Personalized metabolic connectome analysis reveals glucose heterogeneity in ischemic cerebrovascular disease · European Journal of Nuclear Medicine and Molecular Imaging · 2026 · Same journal